Zhejiang Wecome Pharmaceutical Company Limited

SZSE:300878.SZ

23.26 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q1
Revenue 96.177199.95387.619115.563120.7195.73956.942178.726111.839183.784131.541169.582199.57132.26150.375165.856183.782122.755187.511153.496150.397150.397
Cost of Revenue 47.09102.12876.94740.14934.473106.19546.83657.91526.93888.40970.09739.2550.24844.78144.74844.96447.17234.53648.74239.56239.73139.731
Gross Profit 49.08897.82510.67375.41486.22789.54410.106120.81184.90195.37661.444130.332149.32287.479105.627120.892136.6188.219138.769113.934110.666110.666
Gross Profit Ratio 0.510.4890.1220.6530.7140.4570.1770.6760.7590.5190.4670.7690.7480.6610.7020.7290.7430.7190.740.7420.7360.736
Reseach & Development Expenses 3.2482.97122.9323.3827.6428.84211.25310.21610.0437.80821.4276.3175.1794.0927.7235.4391.3465.9015.9215.6054.8174.817
General & Administrative Expenses -7.43210.774-20.4424.762-4.7148.605-20.78925.187-6.248.77-11.32614.911-2.1255.016-9.1476.7166.8057.517-25.4375.5266.0026.002
Selling & Marketing Expenses 53.31552.33784.61839.88843.66240.01848.8948.78636.90557.06343.12381.56390.67154.63256.61173.92782.32755.21575.2675.15370.69270.692
SG&A 58.32563.11164.17964.6538.94848.62328.173.97330.66565.83331.79796.47488.54659.64847.46480.64389.13262.73149.82380.67977.60177.601
Other Expenses -0.058-0.2830.336-4.579-0.122-0.407-1.694-0.053-0.0470.093-0.0273.028-2.2230.108-5.1310.3690.013-0.8970.4450.05700
Operating Expenses 61.6368.629116.33951.52160.19556.40561.18672.15843.573.52172.11795.11793.73663.33255.81482.3682.4968.84186.70884.67877.04877.048
Operating Income -12.54226.634-95.2120.30340.85433.039-53.44246.84439.8426.209-11.09836.46450.0923.68651.72137.77750.50519.03650.83229.38933.69933.699
Operating Income Ratio -0.130.133-1.0870.1760.3380.169-0.9390.2620.3560.143-0.0840.2150.2510.1790.3440.2280.2750.1550.2710.1910.2240.224
Total Other Income Expenses Net 2.289-0.2830.336-4.579-0.122-0.407-1.694-0.053-0.0470.093-0.0270.4360.3690.1080.1780.3690.013-0.8970.4990.057-0.268-0.268
Income Before Tax -10.25326.351-94.87415.72540.73232.632-55.13646.79139.79426.302-11.12536.950.45923.79451.89838.14650.51818.1451.33129.44633.43133.431
Income Before Tax Ratio -0.1070.132-1.0830.1360.3370.167-0.9680.2620.3560.143-0.0850.2180.2530.180.3450.230.2750.1480.2740.1920.2220.222
Income Tax Expense -1.8441.962-17.81710.3773.2244.614-5.6139.6695.4013.173-14.9067.6877.2783.4225.4916.8938.2052.4078.862.8714.9484.948
Net Income -10.14324.335-77.3894.7337.09527.526-49.48736.94534.06622.923.77728.94743.49820.27346.51831.25342.31315.73242.47226.57528.48328.483
Net Income Ratio -0.1050.122-0.8830.0410.3070.141-0.8690.2070.3050.1250.0290.1710.2180.1530.3090.1880.230.1280.2270.1730.1890.189
EPS -0.0710.17-0.630.0330.260.19-0.340.260.240.280.0270.360.650.140.980.220.390.140.390.240.260.26
EPS Diluted -0.0710.17-0.630.0330.260.19-0.340.260.240.280.0270.360.650.140.980.220.390.140.390.240.260.26
EBITDA 2.22230.444-97.6720.25227.04738.752-42.2448.23540.84924.415-9.02439.68154.26525.69553.58839.95454.56818.95154.18429.52535.25635.256
EBITDA Ratio 0.0230.152-1.1150.1750.2240.198-0.7420.270.3650.133-0.0690.2340.2720.1940.3560.2410.2970.1540.2890.1920.2340.234